Podcast
Questions and Answers
Acetazolamide was administered orally to patients in the ADVOR trial.
Acetazolamide was administered orally to patients in the ADVOR trial.
False
The primary endpoint of the ADVOR trial was rehospitalization for heart failure or all-cause death.
The primary endpoint of the ADVOR trial was rehospitalization for heart failure or all-cause death.
False
More patients in the placebo group achieved successful decongestion compared to the acetazolamide group in the ADVOR trial.
More patients in the placebo group achieved successful decongestion compared to the acetazolamide group in the ADVOR trial.
False
Rehospitalization for heart failure or all-cause death occurred in more patients in the acetazolamide group compared to the placebo group in the ADVOR trial.
Rehospitalization for heart failure or all-cause death occurred in more patients in the acetazolamide group compared to the placebo group in the ADVOR trial.
Signup and view all the answers
The length of hospital stay was the same between the acetazolamide and placebo groups in the ADVOR trial.
The length of hospital stay was the same between the acetazolamide and placebo groups in the ADVOR trial.
Signup and view all the answers
Acetazolamide significantly reduced the risk of rehospitalization for heart failure or all-cause death in the ADVOR trial.
Acetazolamide significantly reduced the risk of rehospitalization for heart failure or all-cause death in the ADVOR trial.
Signup and view all the answers
Patients with NT-proBNP level of >1000 pg/mL were excluded from the ADVOR trial.
Patients with NT-proBNP level of >1000 pg/mL were excluded from the ADVOR trial.
Signup and view all the answers
Further data on outcomes and safety are not needed according to the results of the ADVOR trial.
Further data on outcomes and safety are not needed according to the results of the ADVOR trial.
Signup and view all the answers
Acetazolamide was not found to have any impact on other outcomes and adverse events in the ADVOR trial.
Acetazolamide was not found to have any impact on other outcomes and adverse events in the ADVOR trial.
Signup and view all the answers
The ADVOR trial concluded that acetazolamide should not be added to a standard diuretic regimen for aiding decongestion.
The ADVOR trial concluded that acetazolamide should not be added to a standard diuretic regimen for aiding decongestion.
Signup and view all the answers
